Argenx announced that Health Canada has issued a Notice of Compliance authorizing Vyvgart for the treatment of generalized myasthenia gravis, or gMG, in adult patients who are anti-acetylcholine receptor, or AChR, antibody positive. With this regulatory milestone, Vyvgart is the first-and-only neonatal Fc receptor, or FcRn, blocker authorized for sale in Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
- Argenx announces CHMP recommendation for EC approval of SC efgartigimod
- argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
- Argenx price target raised to EUR 560 from EUR 500 at JPMorgan
- Argenx price target raised to $600 from $595 at Piper Sandler